Author:
Li Yuanyuan,Guo Shu'ai,Wu Xinjing,Wan Jiale,Guan Yonghui,Luo Chenghui,Chen Qin,Jiang Hongyu,Lin Haiyan,Qian Hai,Shi Wei,Fan Wen
Funder
National Natural Science Foundation of China
Reference30 articles.
1. Mechanisms of age-related macular degeneration and therapeutic opportunities;van Lookeren Campagne;J. Pathol.,2014
2. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. The Lancet. Global health 2021, 9 (2), e144-e160.
3. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis;Wong;Lancet Glob. Health,2014
4. Ranibizumab for age-related macular degeneration;Dhoot;Expert Opin. Biol. Ther.,2012
5. Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration;Balaratnasingam;Clinical Ophthalmology (auckland, n.z.),2015